Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial

INTRODUCTION: Luseogliflozin, a potent, selective sodium glucose cotransporter 2 inhibitor, promotes urinary glucose excretion (UGE) and reduces plasma glucose concentrations. Luseogliflozin was approved for use in Japan after favorable pharmacokinetic, pharmacodynamic, and safety profiles were repo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Adv Ther
Hlavní autoři: Sasaki, Takashi, Seino, Yutaka, Fukatsu, Atsushi, Ubukata, Michito, Sakai, Soichi, Samukawa, Yoshishige
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Healthcare 2015
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4415995/
https://ncbi.nlm.nih.gov/pubmed/25855342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-015-0200-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky